
|Articles|September 15, 2002
Macugen research: Enrollment ends early in trials for wet AMD drug
New York-Eyetech Pharmaceuticals Inc. has completed enrollment in two phase III trials of Macugen, its treatment for wet age-related macular degeneration (AMD), and has received $54.2 million from investors for further development of the drug.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Lesion growth rate reduction tops retina specialists' geographic atrophy treatment priorities
3
ChatGPT-5 overestimates macular hole surgery success, study finds
4
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
5


























